Results 131 to 140 of about 2,799 (186)
Some of the next articles are maybe not open access.
Pharmacokinetic Considerations of Misonidazole in Therapeutics
Human Toxicology, 1984The pharmacokinetics of misonidazole have been studied in 6 patients with special emphasis on determination of the peak concentration in plasma and saliva. Frequent sampling was performed over 4 h and a marked variation in absorption half-life (range 4 - 125 min) and time to peak range (0.5 - 6.5 h) was found.
I, Matheson, P N, Plowman, A, Johnston
openaire +2 more sources
Neurotoxicity of adriamycin and misonidazole in the mouse
Experimental Neurology, 1985The neurotoxicity of the anticancer drug adriamycin was investigated in the peripheral nerve of the mouse. Injection of adriamycin into the sciatic nerve resulted in biochemical and morphologic signs of severe axonal degeneration. The biochemical evidence was based on marked increases in lysosomal enzyme activity.
R J, Boegman +3 more
openaire +2 more sources
Glutathione conjugates of misonidazole
Biochemical and Biophysical Research Communications, 1983The hydroxylamine derivative of misonidazole reacts with glutathione under physiological conditions to form two isomeric conjugates. Based on physical and chemical properties, the two conjugates have been identified as 1-[2-amino-(4-glutathion-S-yl)-1-imidazolyl]-3-methoxypropanol and 1-[2-amino-(5-glutathion-S-yl)-1-imidazolyl]-3-methoxypropanol.
openaire +2 more sources
Enhancement of Misonidazole Cytotoxicity by Iron
International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1985The toxicity of misonidazole (MISO) to hypoxic Chinese hamster ovary (CHO) cells in serum-free medium is enhanced by Fe(III)-EDTA. Enhancement of MISO cytotoxicity by a factor of 1.6 was seen with 2 microM Fe(III)-EDTA, while 200 microM Fe(III)-EDTA results in sensitization by a factor of 2.0.
A, Samuni +3 more
openaire +2 more sources
Stable reduction product of misonidazole
International Journal of Radiation Oncology*Biology*Physics, 1986The predominant stable product (greater than 80%) of the anaerobic radiation chemical reduction (pH 7, formate, N2O) of misonidazole (MISO) has been identified as the cyclic guanidinium ion MISO-DDI, a 4,5-dihydro-4,5-dihydroxyimidazolium ion. This cation was prepared as its sulfate salt by the reaction of glyoxal and the appropriate N-substituted ...
R, Panicucci +2 more
openaire +2 more sources
Ascorbate-enhanced Cytotoxicity of misonidazole
Nature, 1978MISONIDAZOLE, an electron-affinic, nitroheterocyclic compound (1-(2-nitro-1-imidazole)-3 methoxy-2-propanol, Ro-07-0582) is undergoing preliminary clinical trials, which are exploring its capacity to sensitise hypoxic tumour cells to ionising radiation damage1–4. The drug also possesses a substantial cytotoxic effect, independent of radiation, which is
P D, Josephy, B, Palcic, L D, Skarsgard
openaire +2 more sources
Kinetics of misonidazole enantiomers
Clinical Pharmacology and Therapeutics, 1984The kinetics of misonidazole enantiomers were followed in nine healthy subjects after a single oral dose of racemic misonidazole (1.0 gm/m2). Mean clearance of (+)-misonidazole was 14% greater than that for (-)-misonidazole and mean volume of distribution was slightly greater (3%) for the (+)-enantiomer.
openaire +2 more sources
Radiation-Enhanced Cytotoxicity of Misonidazole
Radiation Research, 1981KORBELIK, M., PALCIC, B., AND SKARSGARD, L. D. Radiation-Enhanced Cytotoxicity of Misonidazole. Radiat. Res. 88, 343-353 (1981). The effect of ionizing radiation on the toxicity of misonidazole to hypoxic mammalian cells was examined. Cell toxicity response (log surviving fraction vs time of exposure to misonidazole in hypoxia) can be approximated by a
M, Korbelik, B, Palcic, L D, Skarsgard
openaire +2 more sources
Chemosensitization of mouse tumors by misonidazole
International Journal of Radiation Oncology*Biology*Physics, 1982The chemosensitizing action of misonidazole when used in combination with chemotherapeutic drugs has been assessed in two mouse tumors. Regrowth delay has been used as the assay, and by producing dose-response curves the effect has been classified as additive or interactive. A very small additive effect was seen with bleomycin and adriamycin.
V S, Randhawa, F A, Stewart, J, Denekamp
openaire +2 more sources
Electroneurographic Investigations of Misonidazole Polyneuropathy
European Neurology, 197913 patients with malignant tumors were treated by the radiosensitizer misonidazole (Ro 07-0582), total dosage 20-29 g. The electrophysiological investigations showed (1) an early increase of distal latency, the motor nerve conduction velocity (NCV) of the peroneal nerve and the NCV of the sural nerve remaining normal or only signlty reduced, and in a ...
B, Mamoli +4 more
openaire +2 more sources